Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Further Reading

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL

15 Jun 2010
FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

15 Jun 2010
Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

14 Jun 2010
Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

14 Jun 2010
Research findings open door to development of new therapies for lymphomas, leukemias

Research findings open door to development of new therapies for lymphomas, leukemias

8 Jun 2010
GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

8 Jun 2010
Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

8 Jun 2010
CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

7 Jun 2010
Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

7 Jun 2010
Green tea component reduces leukemia cells in patients with CLL

Green tea component reduces leukemia cells in patients with CLL

5 Jun 2010
CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

29 May 2010
CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

28 May 2010
Patients with transformed lymphoma show positive response to lenalidomide: Research

Patients with transformed lymphoma show positive response to lenalidomide: Research

27 May 2010
Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

26 May 2010
Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

20 May 2010
Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

3 May 2010
Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

23 Apr 2010
Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

23 Apr 2010
Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

22 Apr 2010
Abbott acquires Facet Biotech

Abbott acquires Facet Biotech

22 Apr 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback